ABBOTT PARK, Ill., July 20, 2016
/PRNewswire/ -- Abbott (NYSE: ABT) today announced financial
results for the second quarter ended June
30, 2016.
- Second-quarter worldwide sales of $5.3
billion increased 3.2 percent on a reported basis and 6.4
percent on an operational basis.
- Reported diluted EPS from continuing operations under GAAP was
$0.40 in the second quarter.
Excluding specified items, adjusted diluted EPS from continuing
operations was $0.55 in the second
quarter, above the previous guidance range.
- Abbott's full-year 2016 EPS for continuing operations under
GAAP is projected to be $1.26 to
$1.36. Projected full-year 2016 adjusted EPS for continuing
operations remains unchanged at $2.14 to
$2.24.
- In July, Abbott received U.S. FDA approval for
AbsorbTM, the only fully dissolving heart stent, as well
as U.S. FDA approval for TECNIS® Symfony intraocular
lenses for the treatment of cataracts, the first and only extended
depth of focus lenses for people with cataracts.
- In the second quarter, Abbott announced the global launch of
AlinIQ, the first-of-its-kind informatics solution with enhanced
capabilities to help diagnostics laboratories increase productivity
and flexibility in managing data throughout hospital networks.
- On April 28, 2016, Abbott
announced an agreement to acquire St. Jude Medical, Inc. The
transaction will create a premier medical device leader with a
highly competitive portfolio that will include an industry-leading
pipeline across cardiovascular, neuromodulation, diabetes and
vision care.
"It was a good quarter," said Miles D.
White, chairman and chief executive officer, Abbott. "We're
particularly pleased with the steady cadence of new product
approvals and recent launches that are contributing to growth,
including FreeStyle Libre, MitraClip, Absorb and Symfony."
SECOND-QUARTER BUSINESS OVERVIEW
Following are sales by business segment and commentary for
the second quarter and first half of the year:
Total Company
($ in millions)
|
|
|
|
|
|
|
|
% Change vs.
2Q15
|
|
|
Sales
2Q16
|
|
|
|
Int'l
|
|
Total
|
|
|
U.S.
|
|
Int'l
|
|
Total
|
|
U.S.
|
|
Reported
|
|
Operational
|
|
Reported
|
|
Operational
|
Total
*
|
|
1,655
|
|
3,678
|
|
5,333
|
|
4.0
|
|
2.8
|
|
7.5
|
|
3.2
|
|
6.4
|
Nutrition
|
|
750
|
|
990
|
|
1,740
|
|
3.0
|
|
0.2
|
|
5.3
|
|
1.4
|
|
4.3
|
Diagnostics
|
|
361
|
|
865
|
|
1,226
|
|
3.0
|
|
4.5
|
|
7.3
|
|
4.1
|
|
6.0
|
Established
Pharmaceuticals
|
--
|
|
980
|
|
980
|
|
n/a
|
|
0.4
|
|
9.5
|
|
0.4
|
|
9.5
|
Medical
Devices
|
|
535
|
|
837
|
|
1,372
|
|
6.1
|
|
6.6
|
|
7.3
|
|
6.4
|
|
6.8
|
|
* Total Abbott Sales
from continuing operations include Other Sales of $15
million.
|
|
|
|
|
|
|
|
|
|
|
|
% Change vs.
1H15
|
|
|
Sales
1H16
|
|
|
|
Int'l
|
|
Total
|
|
|
U.S.
|
|
Int'l
|
|
Total
|
|
U.S.
|
|
Reported
|
|
Operational
|
|
Reported
|
|
Operational
|
Total
*
|
|
3,186
|
|
7,032
|
|
10,218
|
|
3.0
|
|
0.8
|
|
7.0
|
|
1.5
|
|
5.8
|
Nutrition
|
|
1,469
|
|
1,942
|
|
3,411
|
|
3.9
|
|
(1.5)
|
|
4.6
|
|
0.8
|
|
4.3
|
Diagnostics
|
|
700
|
|
1,644
|
|
2,344
|
|
3.3
|
|
3.2
|
|
7.7
|
|
3.2
|
|
6.4
|
Established
Pharmaceuticals
|
--
|
|
1,868
|
|
1,868
|
|
n/a
|
|
(0.3)
|
|
10.2
|
|
(0.3)
|
|
10.2
|
Medical
Devices
|
|
1,001
|
|
1,568
|
|
2,569
|
|
1.2
|
|
2.8
|
|
5.4
|
|
2.1
|
|
3.7
|
|
* Total Abbott Sales
from continuing operations include Other Sales of $26
million.
|
n/a = Not
Applicable.
|
Note: Operational
growth reflects percentage change over the prior year excluding the
impact of exchange rates. In order to compute results excluding the
impact of exchange rates, current year U.S. dollar sales are
multiplied or divided, as appropriate, by the current year average
foreign exchange rates and then those amounts are multiplied or
divided, as appropriate, by the prior year average foreign exchange
rates.
|
Second-quarter 2016 worldwide sales of $5.3 billion increased 3.2 percent on a reported
basis, including an unfavorable 3.2 percent effect of foreign
exchange, and increased 6.4 percent on an operational basis.
International sales increased 2.8 percent on a reported basis
and 7.5 percent on an operational basis in the second quarter.
International operational growth was led by strong performance
across all of Abbott's business segments.
Emerging market sales increased 1.1 percent on a reported basis
and 8.5 percent on an operational basis in the second quarter.
Excluding the impact of Venezuelan operations, emerging market
sales would have increased 4.8 percent on a reported basis and 12.4
percent on an operational basis.
Nutrition
($ in
millions)
|
|
|
|
|
|
|
|
% Change vs.
2Q15
|
|
|
Sales
2Q16
|
|
|
|
Int'l
|
|
Total
|
|
|
U.S.
|
|
Int'l
|
|
Total
|
|
U.S.
|
|
Reported
|
|
Operational
|
|
Reported
|
|
Operational
|
Total
|
|
750
|
|
990
|
|
1,740
|
|
3.0
|
|
0.2
|
|
5.3
|
|
1.4
|
|
4.3
|
Pediatric
|
|
425
|
|
547
|
|
972
|
|
5.8
|
|
(3.4)
|
|
1.6
|
|
0.4
|
|
3.4
|
Adult
|
|
325
|
|
443
|
|
768
|
|
(0.6)
|
|
5.1
|
|
10.3
|
|
2.6
|
|
5.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% Change vs.
1H15
|
|
|
Sales
1H16
|
|
|
|
Int'l
|
|
Total
|
|
|
U.S.
|
|
Int'l
|
|
Total
|
|
U.S.
|
|
Reported
|
|
Operational
|
|
Reported
|
|
Operational
|
Total
|
|
1,469
|
|
1,942
|
|
3,411
|
|
3.9
|
|
(1.5)
|
|
4.6
|
|
0.8
|
|
4.3
|
Pediatric
|
|
828
|
|
1,111
|
|
1,939
|
|
5.3
|
|
(2.8)
|
|
2.9
|
|
0.5
|
|
3.9
|
Adult
|
|
641
|
|
831
|
|
1,472
|
|
2.2
|
|
0.3
|
|
7.0
|
|
1.1
|
|
4.9
|
Worldwide Nutrition sales increased 1.4 percent on a reported
basis in the second quarter, including an unfavorable 2.9 percent
effect of foreign exchange, and increased 4.3 percent on an
operational basis. Excluding the impact of Venezuelan operations,
worldwide Nutrition sales would have increased 3.3 percent on a
reported basis and 6.2 percent on an operational basis.
Worldwide Pediatric Nutrition sales increased 0.4 percent on a
reported basis in the second quarter, including an unfavorable 3.0
percent effect of foreign exchange, and increased 3.4 percent on an
operational basis. Sales growth in the quarter was led by
above-market growth in the U.S. with continued uptake of recently
launched products, including infant and toddler non-GMO products,
as well as strong performance across several countries in
Latin America and Asia.
Worldwide Adult Nutrition sales increased 2.6 percent on a
reported basis in the second quarter, including an unfavorable 2.9
percent effect of foreign exchange, and increased 5.5 percent on an
operational basis. Operational sales growth in the quarter was led
by strong growth of Abbott's complete and balanced nutrition brand,
Ensure®, and double-digit growth
internationally.
Diagnostics
($ in millions)
|
|
|
|
|
|
|
|
% Change vs.
2Q15
|
|
|
Sales
2Q16
|
|
|
|
Int'l
|
|
Total
|
|
|
U.S.
|
|
Int'l
|
|
Total
|
|
U.S.
|
|
Reported
|
|
Operational
|
|
Reported
|
|
Operational
|
Total
|
|
361
|
|
865
|
|
1,226
|
|
3.0
|
|
4.5
|
|
7.3
|
|
4.1
|
|
6.0
|
Core
Laboratory
|
|
206
|
|
772
|
|
978
|
|
0.1
|
|
4.3
|
|
7.1
|
|
3.4
|
|
5.6
|
Molecular
|
|
51
|
|
68
|
|
119
|
|
1.1
|
|
3.6
|
|
5.9
|
|
2.5
|
|
3.8
|
Point of
Care
|
|
104
|
|
25
|
|
129
|
|
10.2
|
|
17.2
|
|
17.4
|
|
11.5
|
|
11.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% Change vs.
1H15
|
|
|
Sales
1H16
|
|
|
|
Int'l
|
|
Total
|
|
|
U.S.
|
|
Int'l
|
|
Total
|
|
U.S.
|
|
Reported
|
|
Operational
|
|
Reported
|
|
Operational
|
Total
|
|
700
|
|
1,644
|
|
2,344
|
|
3.3
|
|
3.2
|
|
7.7
|
|
3.2
|
|
6.4
|
Core
Laboratory
|
|
396
|
|
1,467
|
|
1,863
|
|
1.2
|
|
3.2
|
|
7.8
|
|
2.8
|
|
6.4
|
Molecular
|
|
98
|
|
129
|
|
227
|
|
(0.5)
|
|
0.2
|
|
4.6
|
|
(0.1)
|
|
2.4
|
Point of
Care
|
|
206
|
|
48
|
|
254
|
|
9.7
|
|
12.1
|
|
13.4
|
|
10.1
|
|
10.4
|
Worldwide Diagnostics sales increased 4.1 percent on a reported
basis in the second quarter, including an unfavorable 1.9 percent
effect of foreign exchange, and increased 6.0 percent on an
operational basis.
Core Laboratory Diagnostics sales increased 3.4 percent on a
reported basis in the second quarter, including an unfavorable 2.2
percent effect of foreign exchange, and increased 5.6 percent on an
operational basis. Operational sales growth in the quarter was led
by double-digit growth in emerging markets. During the quarter,
Abbott launched AlinIQ, a first-of-its-kind professional services
and informatics solution that enhances diagnostic laboratory
productivity and flexibility in managing data throughout hospital
networks.
Molecular Diagnostics sales increased 2.5 percent on a reported
basis in the second quarter, including an unfavorable 1.3 percent
effect of foreign exchange, and increased 3.8 percent on an
operational basis. As expected, continued strong growth in Abbott's
infectious disease testing business was partially offset by the
planned scale down of its genetics business.
Point of Care Diagnostics sales increased 11.5 percent on a
reported and operational basis. Double-digit sales growth was led
by continued adoption of Abbott's i-STAT® handheld
system in the U.S. and international markets.
Established Pharmaceuticals
($ in millions)
|
|
|
|
|
|
|
|
% Change vs.
2Q15
|
|
|
Sales
2Q16
|
|
|
|
Int'l
|
|
Total
|
|
|
U.S.
|
|
Int'l
|
|
Total
|
|
U.S.
|
|
Reported
|
|
Operational
|
|
Reported
|
|
Operational
|
Total
|
|
--
|
|
980
|
|
980
|
|
n/a
|
|
0.4
|
|
9.5
|
|
0.4
|
|
9.5
|
Key Emerging
Markets
|
|
--
|
|
754
|
|
754
|
|
n/a
|
|
3.9
|
|
15.9
|
|
3.9
|
|
15.9
|
Other
|
|
--
|
|
226
|
|
226
|
|
n/a
|
|
(9.9)
|
|
(9.1)
|
|
(9.9)
|
|
(9.1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% Change vs.
1H15
|
|
|
Sales
1H16
|
|
|
|
Int'l
|
|
Total
|
|
|
U.S.
|
|
Int'l
|
|
Total
|
|
U.S.
|
|
Reported
|
|
Operational
|
|
Reported
|
|
Operational
|
Total
|
|
--
|
|
1,868
|
|
1,868
|
|
n/a
|
|
(0.3)
|
|
10.2
|
|
(0.3)
|
|
10.2
|
Key Emerging
Markets
|
|
--
|
|
1,388
|
|
1,388
|
|
n/a
|
|
0.5
|
|
14.0
|
|
0.5
|
|
14.0
|
Other
|
|
--
|
|
480
|
|
480
|
|
n/a
|
|
(2.6)
|
|
(0.4)
|
|
(2.6)
|
|
(0.4)
|
Established Pharmaceuticals sales increased 0.4 percent on a
reported basis in the second quarter, including an unfavorable 9.1
percent effect of foreign exchange, and increased 9.5 percent on an
operational basis. Excluding the impact of Venezuelan operations,
Established Pharmaceuticals sales would have increased 4.6 percent
on a reported basis and 14.1 percent on an operational basis.
Key Emerging Markets include India, Russia, Brazil and China, along with several additional emerging
markets that represent the most attractive long-term growth
opportunities for Abbott's branded generics product portfolio.
Sales in these key geographies increased 3.9 percent on a reported
basis and 15.9 percent on an operational basis. Operational sales
growth was led by continued strong growth in India, which comprises more than 20 percent of
Abbott's Established Pharmaceuticals sales, as well as Russia, China
and several countries throughout Latin America.
Medical Devices
($ in millions)
|
|
|
|
|
|
|
|
% Change vs.
2Q15
|
|
|
Sales
2Q16
|
|
|
|
Int'l
|
|
Total
|
|
|
U.S.
|
|
Int'l
|
|
Total
|
|
U.S.
|
|
Reported
|
|
Operational
|
|
Reported
|
|
Operational
|
Total
|
|
535
|
|
837
|
|
1,372
|
|
6.1
|
|
6.6
|
|
7.3
|
|
6.4
|
|
6.8
|
Vascular
|
|
346
|
|
436
|
|
782
|
|
16.4
|
|
2.7
|
|
3.6
|
|
8.3
|
|
8.9
|
Diabetes
Care
|
|
73
|
|
210
|
|
283
|
|
(21.6)
|
|
13.4
|
|
15.2
|
|
1.7
|
|
2.8
|
Medical
Optics
|
|
116
|
|
191
|
|
307
|
|
1.9
|
|
9.1
|
|
7.7
|
|
6.2
|
|
5.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vascular Product
Lines:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Coronary
Devicesa)
|
|
202
|
|
367
|
|
569
|
|
3.9
|
|
1.2
|
|
2.0
|
|
2.1
|
|
2.6
|
Endovascularb)
|
|
77
|
|
68
|
|
145
|
|
8.5
|
|
10.5
|
|
12.3
|
|
9.4
|
|
10.2
|
|
a)
Includes DES / BVS product portfolio, structural heart, guidewires,
balloon catheters and other coronary products.
|
b)
Includes vessel closure, carotid stents and other peripheral
products.
|
|
|
|
|
|
|
|
|
|
|
|
% Change vs.
1H15
|
|
|
Sales
1H16
|
|
|
|
Int'l
|
|
Total
|
|
|
U.S.
|
|
Int'l
|
|
Total
|
|
U.S.
|
|
Reported
|
|
Operational
|
|
Reported
|
|
Operational
|
Total
|
|
1,001
|
|
1,568
|
|
2,569
|
|
1.2
|
|
2.8
|
|
5.4
|
|
2.1
|
|
3.7
|
Vascular
|
|
635
|
|
832
|
|
1,467
|
|
9.3
|
|
(0.8)
|
|
1.9
|
|
3.3
|
|
5.0
|
Diabetes
Care
|
|
142
|
|
384
|
|
526
|
|
(26.8)
|
|
9.3
|
|
13.2
|
|
(3.6)
|
|
(1.1)
|
Medical
Optics
|
|
224
|
|
352
|
|
576
|
|
4.5
|
|
5.0
|
|
6.0
|
|
4.8
|
|
5.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vascular Product
Lines:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Coronary
Devicesa)
|
|
396
|
|
703
|
|
1,099
|
|
4.4
|
|
(2.2)
|
|
0.4
|
|
0.1
|
|
1.8
|
Endovascularb)
|
|
150
|
|
128
|
|
278
|
|
9.0
|
|
6.8
|
|
10.5
|
|
7.9
|
|
9.7
|
|
a)
Includes DES / BVS product portfolio, structural heart, guidewires,
balloon catheters and other coronary products.
|
b)
Includes vessel closure, carotid stents and other peripheral
products.
|
Worldwide Medical Devices sales increased 6.4 percent on a
reported basis in the second quarter, including an unfavorable 0.4
percent effect of foreign exchange, and increased 6.8 percent on an
operational basis.
Worldwide sales of Vascular products increased 8.3 percent on a
reported basis in the second quarter, including an unfavorable 0.6
percent effect of foreign exchange, and increased 8.9 percent on an
operational basis. Sales were favorably impacted by the resolution
of previously disputed third-party royalty revenue related to the
prior year. Excluding this impact, worldwide sales of Vascular
products would have increased 4.1 percent on a reported basis and
4.7 percent on an operational basis, and U.S. sales would have
increased 6.2 percent on a reported and operational basis.
Sales growth in Vascular products was led by double-digit growth
of MitraClip®, Abbott's device for the treatment of
mitral regurgitation, as Abbott continues to build the market for
this first-in-class device. Double-digit operational sales growth
in Abbott's Endovascular business was driven by vessel closure
products and Supera®, Abbott's unique peripheral stent
for the treatment of blockages in the leg. In July, the U.S. FDA
approved Abbott's Absorb bioresorbable stent, the only fully
dissolving heart stent. Absorb offers a unique benefit to patients,
as it is designed to treat coronary artery disease like a metallic
stent, but then disappears after the artery is healed, leaving no
metal behind to restrict natural vessel motion.
Worldwide Diabetes Care sales increased 1.7 percent on a
reported basis in the second quarter, including an unfavorable 1.1
percent effect of foreign exchange, and increased 2.8 percent on an
operational basis. International sales growth was driven by
continued consumer uptake of FreeStyle® Libre, Abbott's
revolutionary Flash Glucose Monitoring System that eliminates
routine finger sticks and finger-stick calibration. In the U.S.,
sales were impacted by competitive and market dynamics.
Worldwide Medical Optics sales increased 6.2 percent on a
reported basis in the second quarter, including a favorable 0.8
percent effect of foreign exchange, and increased 5.4 percent on an
operational basis. Operational sales growth was driven by continued
market uptake of cataract products in the premium intraocular lens
segment. In July, Abbott received U.S. FDA approval for the TECNIS
Symfony intraocular lenses, the first and only lenses in the U.S.
that provide a full range of continuous high-quality vision
following cataract surgery.
ABBOTT'S FULL-YEAR EARNINGS-PER-SHARE GUIDANCE
Abbott projects earnings per share from continuing operations
under Generally Accepted Accounting Principles (GAAP) of
$1.26 to $1.36 for the full year
2016.
Abbott forecasts net specified items for the full year 2016 of
approximately $0.88 per share.
Specified items include intangible amortization expense, the impact
of the Venezuelan currency devaluation in the first quarter,
expenses associated with acquisitions, including bridge facility
fees, and charges related to cost reduction initiatives and other
expenses, partially offset by the favorable resolution of various
tax positions from prior years.
Excluding specified items, projected earnings per share from
continuing operations remains unchanged at $2.14 to $2.24 for the full year 2016.
ABBOTT DECLARES 370TH QUARTERLY DIVIDEND
On June 10, 2016, the board of
directors of Abbott declared the company's quarterly dividend of
$0.26 per share. Abbott's cash
dividend is payable Aug. 15, 2016, to
shareholders of record at the close of business on July 15, 2016.
Abbott is a member of the S&P 500 Dividend Aristocrats
Index, which tracks companies that have annually increased their
dividend for 25 consecutive years.
About Abbott:
Abbott is a global healthcare company devoted to improving life
through the development of products and technologies that span the
breadth of healthcare. With a portfolio of leading, science-based
offerings in diagnostics, medical devices, nutritionals and branded
generic pharmaceuticals, Abbott serves people in more than 150
countries and employs approximately 74,000 people.
Visit Abbott at www.abbott.com and connect with us on Twitter at
@AbbottNews.
Abbott will webcast its live second-quarter earnings conference
call through its Investor Relations website at
www.abbottinvestor.com at 8 a.m. Central
time today. An archived edition of the call will be
available after 11 a.m. Central
time.
— Private Securities Litigation Reform
Act of 1995 —
A Caution Concerning Forward-Looking
Statements
Some statements in this news release may be forward-looking
statements for purposes of the Private Securities Litigation Reform
Act of 1995. Abbott cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those indicated in the
forward-looking statements. Economic, competitive, governmental,
technological and other factors that may affect Abbott's operations
are discussed in Item 1A, "Risk Factors,'' to our Annual Report on
Securities and Exchange Commission Form 10-K for the year ended
Dec. 31, 2015, and are incorporated
by reference. Abbott undertakes no obligation to release publicly
any revisions to forward-looking statements as a result of
subsequent events or developments, except as required by
law.
Abbott Laboratories
and Subsidiaries
|
Condensed
Consolidated Statement of Earnings
|
Second Quarter Ended
June 30, 2016 and 2015
|
(in millions, except
per share data)
|
(unaudited)
|
|
|
|
2Q16
|
|
2Q15
|
|
%
Change
|
|
Net Sales
|
|
$5,333
|
|
$5,170
|
|
3.2
|
|
|
|
|
|
|
|
|
|
Cost of products
sold, excluding amortization expense
|
|
2,287
|
|
2,218
|
|
3.1
|
|
Amortization of
intangible assets
|
|
145
|
|
151
|
|
(4.0)
|
|
Research and
development
|
|
348
|
|
345
|
|
0.9
|
|
Selling, general, and
administrative
|
|
1,737
|
|
1,727
|
|
0.6
|
|
Total Operating Cost
and Expenses
|
|
4,517
|
|
4,441
|
|
1.7
|
|
|
|
|
|
|
|
|
|
Operating
earnings
|
|
816
|
|
729
|
|
11.9
|
|
|
|
|
|
|
|
|
|
Interest expense,
net
|
|
83
|
|
17
|
|
n/m
|
|
Net foreign exchange
(gain) loss
|
|
10
|
|
5
|
|
77.0
|
|
Other (income)
expense, net
|
|
8
|
|
(279)
|
|
n/m
|
1)
|
Earnings from
Continuing Operations before taxes
|
|
715
|
|
986
|
|
(27.4)
|
|
|
|
|
|
|
|
|
|
Tax expense on
Earnings from Continuing Operations
|
|
116
|
|
200
|
|
(42.0)
|
|
Earnings from
Continuing Operations
|
|
599
|
|
786
|
|
(23.8)
|
|
|
|
|
|
|
|
|
|
Earnings (Loss) from
Discontinued Operations, net of taxes
|
|
16
|
|
(1)
|
|
n/m
|
|
Gain (Loss) on Sale
of Discontinued Operations, net of taxes
|
|
--
|
|
(1)
|
|
n/m
|
|
Net Earnings (Loss)
from Discontinued Operations, net of taxes
|
|
16
|
|
(2)
|
|
n/m
|
|
|
|
|
|
|
|
|
|
Net
Earnings
|
|
$615
|
|
$784
|
|
(21.5)
|
|
|
|
|
|
|
|
|
|
Net Earnings from
Continuing Operations, excluding
|
|
|
|
|
|
|
|
Specified Items, as
described below
|
|
$812
|
|
$786
|
|
3.3
|
2)
|
|
|
|
|
|
|
|
|
Diluted Earnings per
Common Share from:
|
|
|
|
|
|
|
|
Continuing
Operations
|
|
$0.40
|
|
$0.52
|
|
(23.1)
|
|
Discontinued
Operations
|
|
0.01
|
|
--
|
|
n/m
|
|
Total
|
|
$0.41
|
|
$0.52
|
|
(21.2)
|
|
|
|
|
|
|
|
|
|
Diluted Earnings per
Common Share from Continuing
|
|
|
|
|
|
|
|
Operations, excluding
Specified Items, as described below
|
|
$0.55
|
|
$0.52
|
|
5.8
|
2)
|
|
|
|
|
|
|
|
|
Average Number of
Common Shares Outstanding
|
|
|
|
|
|
|
|
Plus Dilutive Common
Stock Options
|
|
1,480
|
|
1,504
|
|
|
|
|
NOTES:
|
|
See tables below
for an explanation of certain non-GAAP financial
information.
|
n/m = Percent change
is not meaningful.
|
See footnotes
below.
|
|
|
|
|
1)
|
2015 Other (income)
expense includes a gain on the sale of a portion of Abbott's
position in Mylan stock and a decrease in the fair value of
contingent consideration related to a business acquisition, both
reported as specified items.
|
|
|
2)
|
2016 Net Earnings
from Continuing Operations, excluding Specified Items, excludes net
after-tax charges of $213 million, or $0.15 per share, for
intangible amortization expense, expenses primarily associated with
acquisitions, including bridge facility fees, and charges related
to cost reduction initiatives and other expenses.
|
|
|
|
2015 Net Earnings
from Continuing Operations, excluding Specified Items, excludes net
after-tax charges of less than $1 million as intangible
amortization expense, expenses associated with cost reduction
initiatives and expenses related to acquisitions were offset by a
gain on the sale of a portion of Abbott's position in Mylan stock
and a decrease in the fair value of contingent consideration
related to a business acquisition.
|
Abbott Laboratories
and Subsidiaries
|
Condensed
Consolidated Statement of Earnings
|
First Half Ended June
30, 2016 and 2015
|
(in millions, except
per share data)
|
(unaudited)
|
|
|
|
1H16
|
|
1H15
|
|
%
Change
|
|
Net Sales
|
|
$10,218
|
|
$10,067
|
|
1.5
|
|
|
|
|
|
|
|
|
|
Cost of products
sold, excluding amortization expense
|
|
4,427
|
|
4,299
|
|
3.0
|
|
Amortization of
intangible assets
|
|
289
|
|
307
|
|
(5.8)
|
|
Research and
development
|
|
727
|
|
658
|
|
10.5
|
|
Selling, general, and
administrative
|
|
3,435
|
|
3,464
|
|
(0.8)
|
|
Total Operating Cost
and Expenses
|
|
8,878
|
|
8,728
|
|
1.7
|
|
|
|
|
|
|
|
|
|
Operating
earnings
|
|
1,340
|
|
1,339
|
|
0.1
|
|
|
|
|
|
|
|
|
|
Interest expense,
net
|
|
108
|
|
33
|
|
n/m
|
|
Net foreign exchange
(gain) loss
|
|
488
|
|
(49)
|
|
n/m
|
1)
|
Other (income)
expense, net
|
|
27
|
|
(284)
|
|
n/m
|
|
Earnings from
Continuing Operations before taxes
|
|
717
|
|
1,639
|
|
(56.3)
|
|
|
|
|
|
|
|
|
|
Tax expense on
Earnings from Continuing Operations
|
|
62
|
|
324
|
|
(80.9)
|
2)
|
Earnings from
Continuing Operations
|
|
655
|
|
1,315
|
|
(50.2)
|
|
|
|
|
|
|
|
|
|
Earnings from
Discontinued Operations, net of taxes
|
|
260
|
|
25
|
|
n/m
|
|
Gain on Sale of
Discontinued Operations, net of taxes
|
|
16
|
|
1,736
|
|
(99.1)
|
|
Net Earnings from
Discontinued Operations, net of taxes
|
|
276
|
|
1,761
|
|
(84.3)
|
3)
|
|
|
|
|
|
|
|
|
Net
Earnings
|
|
$931
|
|
$3,076
|
|
(69.7)
|
|
|
|
|
|
|
|
|
|
Net Earnings from
Continuing Operations, excluding
|
|
|
|
|
|
|
|
Specified Items, as
described below
|
|
$1,427
|
|
$1,505
|
|
(5.2)
|
4)
|
|
|
|
|
|
|
|
|
Diluted Earnings per
Common Share from:
|
|
|
|
|
|
|
|
Continuing
Operations
|
|
$0.44
|
|
$0.87
|
|
(49.4)
|
|
Discontinued
Operations
|
|
0.19
|
|
1.16
|
|
(83.6)
|
3)
|
Total
|
|
$0.63
|
|
$2.03
|
|
(69.0)
|
|
|
|
|
|
|
|
|
|
Diluted Earnings per
Common Share from Continuing
|
|
|
|
|
|
|
|
Operations, excluding
Specified Items, as described below
|
|
$0.96
|
|
$0.99
|
|
(3.0)
|
4)
|
|
|
|
|
|
|
|
|
Average Number of
Common Shares Outstanding
|
|
|
|
|
|
|
|
Plus Dilutive Common
Stock Options
|
|
1,482
|
|
1,511
|
|
|
|
|
NOTES:
|
|
See tables below
for an explanation of certain non-GAAP financial
information.
|
n/m = Percent change
is not meaningful.
|
See footnotes
below.
|
|
|
|
|
1)
|
2016 Net foreign
exchange (gain) loss includes a loss of $477 million related to the
revaluation of Abbott's net monetary assets in Venezuela using the
Dicom exchange rate, which is the Venezuelan government's official
floating exchange rate.
|
|
|
2)
|
2016 Tax expense on
Earnings from Continuing Operations includes the impact of a net
tax benefit of approximately $145 million as a result of the
resolution of various tax positions from prior years, partially
offset by the unfavorable impact of non-deductible foreign exchange
losses related to Venezuela.
|
|
|
3)
|
2016 Earnings and
Diluted Earnings per Common Share from Discontinued Operations, net
of taxes primarily reflect the impact of a net tax benefit of $266
million as a result of the resolution of various tax positions from
prior years.
|
|
|
|
2015 Earnings and
Diluted Earnings per Common Share from Discontinued Operations, net
of taxes reflect the after-tax gain of $1.736 billion on the sale
of the developed markets branded generics pharmaceuticals and
animal health businesses to Mylan on Feb. 27, 2015 and Zoetis on
Feb. 10, 2015, respectively; the first-quarter financial results
from these businesses up to the date of sale; and a favorable
adjustment to tax expense as a result of the resolution of various
tax positions from previous years related to AbbVie
operations.
|
|
|
4)
|
2016 Net Earnings
from Continuing Operations, excluding Specified Items, excludes net
after-tax charges of $772 million, or $0.52 per share, for
intangible amortization expense, the foreign exchange loss related
to Venezuela, expenses associated with acquisitions, including
bridge facility fees, and other charges related to cost reduction
initiatives and other expenses, partially offset by the favorable
impact of a net tax benefit as a result of the resolution of
various tax positions from prior years.
|
|
|
|
2015 Net Earnings
from Continuing Operations, excluding Specified Items, excludes net
after-tax charges of $190 million, or $0.12 per share, for
intangible amortization expense, expenses associated with cost
reduction initiatives and expenses related to acquisitions,
partially offset by a gain on the sale of a portion of Abbott's
position in Mylan stock and a decrease in the fair value of
contingent consideration related to a business
acquisition.
|
NON-GAAP
RECONCILIATION OF FINANCIAL INFORMATION FROM CONTINUING
OPERATIONS
|
|
Abbott Laboratories
and Subsidiaries
|
Non-GAAP
Reconciliation of Financial Information From Continuing
Operations
|
Second Quarter Ended
June 30, 2016 and 2015
|
(in millions, except
per share data)
|
(unaudited)
|
|
|
|
2Q16
|
|
|
As
Reported
(GAAP)
|
|
Specified
Items
|
|
As
Adjusted
|
|
% to
Sales
|
|
|
|
|
|
|
|
|
|
Intangible
Amortization
|
|
$145
|
|
($145)
|
|
--
|
|
|
Gross
Margin
|
|
2,901
|
|
170
|
|
$3,071
|
|
57.6%
|
R&D
|
|
348
|
|
(1)
|
|
347
|
|
6.5%
|
SG&A
|
|
1,737
|
|
(54)
|
|
1,683
|
|
31.6%
|
Interest expense,
net
|
|
83
|
|
(57)
|
|
26
|
|
|
Other (income)
expense, net
|
|
8
|
|
(1)
|
|
7
|
|
|
Earnings from
Continuing Operations before taxes
|
|
715
|
|
283
|
|
998
|
|
|
Taxes on Earnings
from Continuing Operations
|
|
116
|
|
70
|
|
186
|
|
|
Net Earnings from
Continuing Operations
|
|
599
|
|
213
|
|
812
|
|
|
Diluted Earnings per
Share from Continuing Operations
|
|
$0.40
|
|
$0.15
|
|
$0.55
|
|
|
Specified items reflect intangible amortization expense of
$145 million, and other expenses of
$138 million, primarily associated
with acquisitions, including bridge facility fees, and charges
related to cost reduction initiatives and other expenses.
|
|
2Q15
|
|
|
As
Reported
(GAAP)
|
|
Specified
Items
|
|
As
Adjusted
|
|
% to
Sales
|
|
|
|
|
|
|
|
|
|
Intangible
Amortization
|
|
$151
|
|
($151)
|
|
--
|
|
|
Gross
Margin
|
|
2,801
|
|
185
|
|
$2,986
|
|
57.8%
|
R&D
|
|
345
|
|
(20)
|
|
325
|
|
6.3%
|
SG&A
|
|
1,727
|
|
(67)
|
|
1,660
|
|
32.1%
|
Other (income)
expense, net
|
|
(279)
|
|
287
|
|
8
|
|
|
Earnings from
Continuing Operations before taxes
|
|
986
|
|
(15)
|
|
971
|
|
|
Taxes on Earnings
from Continuing Operations
|
|
200
|
|
(15)
|
|
185
|
|
|
Net Earnings from
Continuing Operations
|
|
786
|
|
--
|
|
786
|
|
|
Diluted Earnings per
Share from Continuing Operations
|
|
$0.52
|
|
--
|
|
$0.52
|
|
|
Specified items reflect intangible amortization expense of
$151 million and other expenses of
$121 million, primarily associated
with cost reduction initiatives and acquisitions, partially offset
by a gain on the sale of a portion of Abbott's position in Mylan
stock of $207 million and a decrease
in the fair value of contingent consideration related to a business
acquisition.
Abbott Laboratories
and Subsidiaries
|
Non-GAAP
Reconciliation of Financial Information From Continuing
Operations
|
First Half Ended June
30, 2016 and 2015
|
(in millions, except
per share data)
|
(unaudited)
|
|
|
|
1H16
|
|
|
As
Reported
(GAAP)
|
|
Specified
Items
|
|
As
Adjusted
|
|
% to
Sales
|
|
|
|
|
|
|
|
|
|
Intangible
Amortization
|
|
$289
|
|
($289)
|
|
--
|
|
|
Gross
Margin
|
|
5,502
|
|
342
|
|
$5,844
|
|
57.2%
|
R&D
|
|
727
|
|
(46)
|
|
681
|
|
6.7%
|
SG&A
|
|
3,435
|
|
(97)
|
|
3,338
|
|
32.7%
|
Interest expense,
net
|
|
108
|
|
(69)
|
|
39
|
|
|
Net foreign exchange
(gain) loss
|
|
488
|
|
(477)
|
|
11
|
|
|
Other (income)
expense, net
|
|
27
|
|
(5)
|
|
22
|
|
|
Earnings from
Continuing Operations before taxes
|
|
717
|
|
1,036
|
|
1,753
|
|
|
Taxes on Earnings
from Continuing Operations
|
|
62
|
|
264
|
|
326
|
|
|
Net Earnings from
Continuing Operations
|
|
655
|
|
772
|
|
1,427
|
|
|
Diluted Earnings per
Share from Continuing Operations
|
|
$0.44
|
|
$0.52
|
|
$0.96
|
|
|
Specified items reflect intangible amortization expense of
$289 million, the impact of the
foreign exchange loss in Venezuela
of $477 million, and other expenses
of $270 million, primarily associated
with acquisitions, including bridge facility fees, and charges
related to cost reduction initiatives and other expenses, partially
offset by a net tax benefit of approximately $145 million as a result of the resolution of
various tax positions from prior years.
|
|
1H15
|
|
|
As
Reported
(GAAP)
|
|
Specified
Items
|
|
As
Adjusted
|
|
% to
Sales
|
|
|
|
|
|
|
|
|
|
Intangible
Amortization
|
|
$307
|
|
($307)
|
|
--
|
|
|
Gross
Margin
|
|
5,461
|
|
371
|
|
$5,832
|
|
57.9%
|
R&D
|
|
658
|
|
(22)
|
|
636
|
|
6.3%
|
SG&A
|
|
3,464
|
|
(109)
|
|
3,355
|
|
33.3%
|
Other (income)
expense, net
|
|
(284)
|
|
282
|
|
(2)
|
|
|
Earnings from
Continuing Operations before taxes
|
|
1,639
|
|
220
|
|
1,859
|
|
|
Taxes on Earnings
from Continuing Operations
|
|
324
|
|
30
|
|
354
|
|
|
Net Earnings from
Continuing Operations
|
|
1,315
|
|
190
|
|
1,505
|
|
|
Diluted Earnings per
Share from Continuing Operations
|
|
$0.87
|
|
$0.12
|
|
$0.99
|
|
|
Specified items reflect intangible amortization expense of
$307 million and other expenses of
$200 million, primarily associated
with cost reduction initiatives and acquisitions, partially offset
by a gain on the sale of a portion of Abbott's position in Mylan
stock of $207 million and a decrease
in the fair value of contingent consideration related to a business
acquisition.
RECONCILIATION OF TAX RATE FOR CONTINUING OPERATIONS
A reconciliation of the second-quarter tax rates for continuing
operations for 2016 and 2015 is shown below:
|
|
|
2Q16
|
($ in
millions)
|
|
Pre-Tax
Income
|
|
Taxes on
Earnings
|
|
Tax
Rate
|
As reported
(GAAP)
|
|
$715
|
|
$116
|
|
16.2%
|
Specified
items
|
|
283
|
|
70
|
|
|
Excluding
specified items
|
|
$998
|
|
$186
|
|
18.6%
|
|
|
|
|
|
|
|
|
|
|
|
2Q15
|
($ in
millions)
|
|
Pre-Tax
Income
|
|
Taxes on
Earnings
|
|
Tax
Rate
|
As reported
(GAAP)
|
|
$986
|
|
$200
|
|
20.2%
|
Specified
items
|
|
(15)
|
|
(15)
|
|
|
Excluding
specified items
|
|
$971
|
|
$185
|
|
19.0%
|
A reconciliation of the year-to-date tax rates for continuing
operations for 2016 and 2015 is shown below:
|
|
|
1H16
|
|
($ in
millions)
|
|
Pre-Tax
Income
|
|
Taxes on
Earnings
|
|
Tax
Rate
|
|
As reported
(GAAP)
|
|
$717
|
|
$62
|
|
8.6%
|
1)
|
Specified
items
|
|
1,036
|
|
264
|
|
|
|
Excluding
specified items
|
|
$1,753
|
|
$326
|
|
18.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1H15
|
|
($ in
millions)
|
|
Pre-Tax
Income
|
|
Taxes on
Earnings
|
|
Tax
Rate
|
|
As reported
(GAAP)
|
|
$1,639
|
|
$324
|
|
19.7%
|
|
Specified
items
|
|
220
|
|
30
|
|
|
|
Excluding
specified items
|
|
$1,859
|
|
$354
|
|
19.0%
|
|
|
|
1)
|
Reported tax rate on
a GAAP basis for 2016 includes the impact of a net tax benefit of
approximately $145 million as a result of the resolution of various
tax positions from prior years, partially offset by the unfavorable
impact of non-deductible foreign exchange losses related to
Venezuela.
|
Logo - http://photos.prnewswire.com/prnh/20150928/271488LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abbott-reports-second-quarter-2016-results-300301309.html
SOURCE Abbott